Dr Kalinsky on the Role of Tumor Boards in Metastatic Breast Cancer Management | OncLive Kevin Kalinsky, MD, MS, FASCO, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer.

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer. #MBCC26 #bcsm #oncology
www.onclive.com/view/dr-kali...

Want to learn more about the presentations from #MBCC26? #bcsm experts share takeaways and lingering questions from the meeting.

⭐ Sign up to read: www.onclive.com/view/multidi...

@kalinskykevin.bsky.social @winshipcancer.emory.edu @mskcancercenter.bsky.social @fredhutch.org #bcsm #oncology

Another highlight from #MBCC26: Sara Nunnery, MD's conversation with Neil Iyengar, MD, for the upcoming Breast Cancer Briefing podcast! Can't wait for the series to launch? Neither can we. In the meantime, check out our other #bcsm coverage from the meeting! #Oncology
www.onclive.com/conference/m...

We had a blast at last night's closing reception for #MBCC26! What a fantastic way to end another successful year of sharing breast #oncology insights under the beautiful Miami sky. Until next year! #bcsm

It's always great to speak with @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, who sat down with us at #MBCC26 to highlight considerations across the realm of metastatic breast cancer management! See our site for this conversation and more. #bcsm #oncology
www.onclive.com/conference/m...

A huge thanks to Meghan R. Flanagan, MD, MPH, of @fredhutch.org, for stopping by during #MBCC26 to talk all things breast surgical oncology! Head to our site for exclusive commentary from Dr Flanagan and more. #bcsm #oncology
www.onclive.com/conference/m...

Dr Kalinsky on Multidisciplinary Considerations for ESR1+ Breast Cancer Care | OncLive Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer. #MBCC26 #bcsm #oncology
www.onclive.com/view/dr-kali...

Dr Flanagan on the Importance of Multidisciplinary Breast Cancer Tumor Boards | OncLive Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

WATCH: Meghan R. Flanagan, MD, MPH, of @fredhutch.org, notes the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies. #MBCC26 #bcsm #Oncology
www.onclive.com/view/dr-flan...

Jakel on a Multidisciplinary Discussion About Individualized Breast Cancer Management | OncLive Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

WATCH: Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference. #mbcc26 #bcsm #Oncology
www.onclive.com/view/jakel-o...

ctDNA in Early-Stage Breast Cancer: Prognostic Power vs Clinical Actionability | OncLive Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Is ctDNA ready for primetime in early-stage breast cancer? Heather A. Parsons, MD, MPH, breaks down what's known regarding the prognostic value of ctDNA and how this biomarker could affect clinical practice #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/ctdna-i...

Real-World Analysis Highlights Tolerability of T-DXd in HER2-Low Metastatic Breast Cancer Treated in a Community Setting | OncLive T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A real-world analysis showed T-DXd led to toxicity-related discontinuation at rates similar to those from the DESTINY-Breast04 trial in patients with metastatic HER2-low breast cancer treated in the community setting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/real-wo...

Rugo Spotlights Multidisciplinary Insights of Interest at the 43rd Annual Miami Breast Cancer Conference | OncLive Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

The 43rd Annual Miami Breast Cancer Conference is underway. To help you prepare, @hoperugo.bsky.social sat down with OncLive to preview some of the top sessions, talks, and workshops headlining this year's meeting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/rugo-sp...